PHAR Earnings

PHAR reported its earnings on 2026-05-07, showcasing a revenue of 72.45M against an estimate of 93.75M, resulting in a -22.72% surprise. The EPS was -0.07, surpassing the expected 0.05 by -240%. The stock experienced a -26.83% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PHAR's earnings announcement on 2026-05-07, the stock price moved by -26.83% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PHAR's stock price tends to shift by an average of 5.28% in the 10 days leading up to earnings and 3.04% in the 10 days following, providing insight into potential market.

For , analysts estimate PHAR's annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PHAR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PHAR's stock price typically moves by 5.28% in the 10 days before its earnings and 3.04% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call reveals strong financial discipline, positive operating cash flow, and strategic growth plans for RUCONEST and Joenja, including international expansion. Despite a slight revenue drop for RUCONEST, new enrollments and prescribers provide a sustainable growth outlook. The Q&A section indicates confidence in future growth, particularly in Joenja’s international markets. However, management’s lack of clarity on specific metrics could cause some investor caution. Overall, the positive growth outlook and financial discipline suggest a positive stock price movement within the 2% to 8% range over the next two weeks.